MSLN and esophageal adenocarcinoma: Previously described high MSLN positivity rates range from 55% to 100% in ovarian cancer [35,43,44,53], 59% to 76% in endometrium cancer [5,8], 57% to 100% in pancreatic adenocarcinoma [43,47,54], 45% to 100% in malignant mesothelioma [33,43,55,56], 38% to 69% of lung adenocarcinomas [37,38,39], 45% to 78% in stomach cancer [5,45,57,58], 29% to 46% in esophageal adenocarcinoma [6,59], and 30% to 68% of colorectal adenocarcinoma [5,8].